Search
Displaying 191–200 of 728 for “retinal diseases”
-
Ted and Elaine Welp Enhanced Career Development Program Award (Enhanced CDA)
Objective/Goal: The objective of this program is to support the recruitment and retention of a strong pool of physician scientists with a commitment to clinical research on these diseases. Support and protected time will be provided to individuals with M.D. and M.D. /Ph.D. degrees for career development in clinical research leading to research independence in the field of retinal degenerative diseases. This program supports up to two mid-senior level faculty for three (3) years. $170,000/year
-
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Research NewsEditas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
Disease
X-linked retinoschisis (XLRS) is an inherited retinal disease causing vision loss due to splitting of the layers of the retina.
-
Need-to-Know Information about Clinical Trials
Research NewsA primer on what you can expect from clinical trials.
-
Research News
More good news about treatments and technological advances for restoring vision for people with retinal diseases.
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Research News
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Foundation News
This two-day golf tournament at Sanctuary Golf Course will help accelerate research toward treatments and cures for blinding diseases.
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
